A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was: in patients with non-small-cell lung cancer that is found to be unresectable at thoracotomy, is incomplete resection superior for achieving survival advantage? Altogether more than 400 papers were found using the reported search, of which nine represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers were tabulated. In total, data from an estimated 1083 patients were analysed. Three-year survival rates varied from 0 to 22% in incomplete resection and from 0 to 10% in exploratory thoracotomy. Median survival ranged from 6.5 to 19.1 months in incomplete resection and from 5.3 to 17 months in exploratory thoracotomy. The majority of studies (8/9) found survival in incomplete resection to be superior. However, only 3/9 studies presented statistical analysis of results. The largest of these found superior postoperative survival in incomplete resection (including residual nodal disease), one study showed a significant survival difference for R1 but not R2 resection and another with small patient numbers (n = 29) found no significant difference. We conclude that the best evidence suggests that there may be a survival advantage from incomplete resection of non-small-cell lung cancer when there is microscopic (R1) or nodal residual disease, but not when macroscopic residual (R2) disease remains.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] . 
THREE-PART QUESTION

CLINICAL SCENARIO
You are beginning a left upper lobectomy on a patient with non-small-cell lung cancer (NSCLC). The patient is a previously healthy 58-year old, staging bronchoscopy and mediastinoscopy were negative and preoperative imaging revealed no evidence of metastatic spread. You expect the carcinoma to be resectable and the patient to have a good prognosis. Unfortunately, as you inspect the carcinoma on the operating table, you realize that it is adherent to the aorta and complete resection will be impossible. You explain to your assisting SHO that this will be an 'open-and-close' case. The SHO asks whether it might be worthwhile to remove as much of the carcinoma as possible. You are not sure whether there would be a survival advantage to incomplete resection of an NSCLC in this situation, and resolve to check the literature yourself.
SEARCH STRATEGY
Medline 1950 to August 2012 using OVID interface. The search terms were ('non-small-cell-lung' or 'lung-cancer' or 'bronchogeniccarcinoma') and ('incomplete-resection' or 'exploratorythoracotomy' or 'mediastinal invasion' or 'chest-wall-invasion'). Continued that provided the best evidence to answer the question. These are presented in Table 1 .
RESULTS
The best evidence available comes from small numbers of patients within large retrospective studies that were not designed to answer this question, so the evidence is not high quality. Nine studies were found that included survival data on both incomplete resection and exploratory thoracotomy, of which two used the same data set [2, 3] and another two may have had some overlap [4, 5] . In total, data from an estimated 1083 patients were analysed. Three-year survival rates ranged from 0 to 22% in incomplete resection and from 0 to 10% in exploratory thoracotomy. Median survival was reported in five studies [2, [4] [5] [6] [7] and ranged from 6.5 to 19.1 months in incomplete resection and from 5.3 to 17 months in exploratory thoracotomy. The meaning of the term 'incomplete resection' of NSCLC has unfortunately been a matter of controversy. Five studies [3, 4, [6] [7] [8] used it to mean residual disease at the resection margin, two [2, 5] included residual nodal disease and in two [9, 10] , the definition used was not clear. Ichinose et al. [4] studied 29 patients where complete resection was impossible because of the extent of the primary carcinoma, who underwent either incomplete resection (n = 9, median survival 6.5 months) or exploratory thoracotomy (n = 20, median survival 17 months). There was no significant difference in survival (P = 0.27). The authors did not differentiate between R1 and R2 residual disease, but excluded patients with microscopic residual at bronchial stump, and recommended that grossly incomplete resection should be abandoned in favour of radiotherapy.
Yang et al. [6] reported a series of 40 patients with T4 NSCLC with mediastinal invasion, following R1 resection (n = 16, median survival 19.2 months), R2 resection (n = 9, median survival 12.0 months) or exploratory thoracotomy (n = 15, median survival 5.3 months). Survival was superior to exploratory thoracotomy in R1 resection (P = 0.001), but not in R2 resection (P = 0.376). This is the only study found that separated R1 and R2 resection and provides the best evidence that R2 resection does not provide survival advantage over thoracotomy alone.
Rami-Porta et al. [2] reported a large set of 5-year survival data that included patients who underwent incomplete resection (n = 287) or exploratory thoracotomy (n = 274). Excluding operative mortality (12% in incomplete resection and 6% in exploratory thoracotomy), there was superior survival in incomplete resection (P < 0.0001). No distinction was made between R1 and R2 residual disease, and 36% of incomplete resections were due to residual nodal disease rather than primary carcinoma. This is the largest study found and provides the strongest evidence that incomplete resection (including residual nodal disease) may improve postoperative survival.
Hara et al. [5] reported survival data of 227 patients with stage III NSCLC who had incomplete resection (n = 64, median survival 15 months), exploratory thoracotomy (n = 52, median survival 11 months) or conservative management (n = 113, median survival 13 months). They found survival curves to be 'nearly identical' in the three groups, but did not present statistical analysis. The authors included residual nodal disease in incomplete resection and concluded that reduction of tumour volume by incomplete resection did not improve survival.
Taken together, only three papers reported statistical analysis of survival data. Of these, one reported superior survival in incomplete resection (including residual nodal disease) [2] , one reported no difference in survival [4] and one reported increased survival in R1 but not R2 resection [6] . Seven studies reported 2-, 3-or 5-year survival rates, in 6/7 survival was better in incomplete resection [2, 4, [7] [8] [9] [10] and in 1/7 it was equal at 0% [6] . Five studies reported median survival, in 4/5 it was better in incomplete resection [2, [5] [6] [7] and in 1/5 it was better in exploratory thoracotomy [4] . If the five studies that defined an incomplete resection as positive resection margins are taken separately, 1/5 found no significant difference in survival [4] , 1/5 found significantly increased survival in R1 but not R2 resection [6] and 3/5 [3, 7, 8] found superior survival in incomplete resection, but did not present statistical analysis.
CLINICAL BOTTOM LINE
The research undertaken to investigate whether incomplete resection gives any survival benefit over exploratory thoracotomy in NSCLC is not high quality and does not provide a definite conclusion. Interpretation of results is restricted by lack of information about the clinical characteristics of patients undergoing different procedures, and varying definitions of incomplete resection. Overall, 8/9 studies found survival in incomplete resection to be better than in exploratory thoracotomy. One-ninth found mixed results, as median survival in incomplete resection was worse, but 3-year survival was better. However, only 3/9 studies reported statistical analysis. Of these, one showed a significantly better survival in R1 but not in R2 resection [6] , one with small patient numbers showed no significant difference [4] and one showed superior postoperative survival in incomplete resection (including residual nodal disease) compared with exploratory thoracotomy [2] . In summary, the best evidence suggests that there may be a survival advantage from incomplete resection of NSCLC when there is microscopic (R1) or nodal residual disease, but not when macroscopic residual (R2) disease remains.
Conflict of interest: none declared
